Showing results (61-70 of 134) with videos related to
Sort By:
Pageof 14
Annual Review of Medicine|August 25, 2010
Muscle wasting in cancer cachexia: clinical implications, diagnosis, and emerging treatment strategiesShontelle Dodson, Vickie E Baracos, Aminah Jatoi, et al.Plos One|July 30, 2014
Selective androgen receptor modulators (SARMs) negatively regulate triple-negative breast cancer growth and epithelial:mesenchymal stem cell signalingRamesh Narayanan, Sunjoo Ahn, Misty D Cheney, et al.Expert Opinion on Investigational Drugs|March 1, 2006
Toremifene--a promising therapy for the prevention of prostate cancer and complications of androgen deprivation therapySamir S Taneja, Matthew R Smith, James T Dalton, et al.The Journal of Pharmacology and Experimental Therapeutics|May 7, 2010
Nonsteroidal selective androgen receptor modulators enhance female sexual motivationAmanda Jones, Dong Jin Hwang, Charles B Duke, et al.Pharmaceutical Research|October 26, 2006
Selective Androgen Receptor Modulator (SARM) treatment prevents bone loss and reduces body fat in ovariectomized ratsJeffrey D Kearbey, Wenqing Gao, Ramesh Narayanan, et al.Expert Opinion on Therapeutic Patents|May 16, 2012
Androgen receptor antagonists: a patent review (2008-2011)Michael L Mohler, Christopher C Coss, Charles B Duke, et al.International Journal of Oncology|December 4, 2009
Pharmacokinetics, biodistribution and metabolism of a novel selective androgen receptor modulator designed for prostate cancer imagingJun Yang, Zengru Wu, Di Wu, et al.Journal of Medicinal Chemistry|July 9, 2004
A ligand-based approach to identify quantitative structure-activity relationships for the androgen receptorCasey E Bohl, Cheng Chang, Michael L Mohler, et al.Cancer Chemotherapy and Pharmacology|April 13, 2010
A novel bis-indole destabilizes microtubules and displays potent in vitro and in vivo antitumor activity in prostate cancerSunjoo Ahn, Dong Jin Hwang, Christina M Barrett, et al.Endocrinology|August 17, 2004
Comparison of the pharmacological effects of a novel selective androgen receptor modulator, the 5alpha-reductase inhibitor finasteride, and the antiandrogen hydroxyflutamide in intact rats: new approach for benign prostate hyperplasiaWenqing Gao, Jeffrey D Kearbey, Vipin A Nair, et al.Pageof 14